Annual CFF
-$562.20 M
-$494.50 M-730.43%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual cash flow from financing activities is currently -$562.20 million, with the most recent change of -$494.50 million (-730.43%) on 31 December 2023. During the last 3 years, it has fallen by -$56.90 million (-11.26%). VRTX annual CFF is now -156.28% below its all-time high of $999.01 million, reached on 31 December 2009.VRTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$387.50 M
-$28.90 M-8.06%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly cash flow from financing activities is currently -$387.50 million, with the most recent change of -$28.90 million (-8.06%) on 30 September 2024. Over the past year, it has dropped by -$222.50 million (-134.85%). VRTX quarterly CFF is now -171.94% below its all-time high of $538.66 million, reached on 31 December 2009.VRTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$1.22 B
-$222.50 M-22.23%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM cash flow from financing activities is currently -$1.22 billion, with the most recent change of -$222.50 million (-22.23%) on 30 September 2024. Over the past year, it has dropped by -$821.20 million (-204.18%). VRTX TTM CFF is now -222.46% below its all-time high of $999.01 million, reached on 31 December 2009.VRTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -730.4% | -134.8% | -204.2% |
| 3 y3 years | -11.3% | +41.0% | +3.4% |
| 5 y5 years | -689.4% | -2003.6% | -801.6% |
VRTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -730.4% | +62.0% | -912.4% | +41.0% | -1707.1% | +17.2% |
| 5 y | 5 years | -543.4% | +62.0% | -340.0% | +41.0% | -1064.8% | +17.2% |
| alltime | all time | -156.3% | +62.0% | -171.9% | +41.0% | -222.5% | +17.2% |
Vertex Pharmaceuticals Incorporated Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$387.50 M(+8.1%) | -$1.22 B(+22.2%) |
| June 2024 | - | -$358.60 M(+0.3%) | -$1.00 B(+60.1%) |
| Mar 2024 | - | -$357.50 M(+198.4%) | -$625.00 M(+11.2%) |
| Dec 2023 | -$562.20 M(+730.4%) | -$119.80 M(-27.4%) | -$562.20 M(+39.8%) |
| Sept 2023 | - | -$165.00 M(-1053.8%) | -$402.20 M(+35.2%) |
| June 2023 | - | $17.30 M(-105.9%) | -$297.40 M(+11.4%) |
| Mar 2023 | - | -$294.70 M(-833.1%) | -$267.00 M(+294.4%) |
| Dec 2022 | -$67.70 M(-95.4%) | $40.20 M(-166.8%) | -$67.70 M(-84.8%) |
| Sept 2022 | - | -$60.20 M(-226.2%) | -$444.10 M(-57.3%) |
| June 2022 | - | $47.70 M(-150.0%) | -$1.04 B(-1.3%) |
| Mar 2022 | - | -$95.40 M(-71.6%) | -$1.05 B(-28.6%) |
| Dec 2021 | -$1.48 B(+192.5%) | -$336.20 M(-48.8%) | -$1.48 B(+16.7%) |
| Sept 2021 | - | -$656.70 M(-2054.5%) | -$1.27 B(+68.7%) |
| June 2021 | - | $33.60 M(-106.5%) | -$751.00 M(+13.0%) |
| Mar 2021 | - | -$518.70 M(+314.3%) | -$664.57 M(+31.5%) |
| Dec 2020 | -$505.30 M(-498.5%) | -$125.21 M(-11.0%) | -$505.30 M(+131.1%) |
| Sept 2020 | - | -$140.68 M(-217.2%) | -$218.64 M(+279.6%) |
| June 2020 | - | $120.03 M(-133.4%) | -$57.60 M(-69.8%) |
| Mar 2020 | - | -$359.43 M(-322.6%) | -$190.64 M(-250.3%) |
| Dec 2019 | $126.80 M(-278.0%) | $161.45 M(+693.1%) | $126.80 M(-193.4%) |
| Sept 2019 | - | $20.36 M(-256.4%) | -$135.69 M(-11.9%) |
| June 2019 | - | -$13.02 M(-69.0%) | -$153.97 M(-19.9%) |
| Mar 2019 | - | -$41.99 M(-58.4%) | -$192.16 M(+169.8%) |
| Dec 2018 | -$71.22 M(-204.1%) | -$101.05 M(-4960.3%) | -$71.22 M(-169.1%) |
| Sept 2018 | - | $2.08 M(-104.1%) | $103.06 M(-59.4%) |
| June 2018 | - | -$51.21 M(-164.9%) | $253.68 M(-41.9%) |
| Mar 2018 | - | $78.96 M(+7.8%) | $436.93 M(+538.7%) |
| Dec 2017 | $68.40 M(-48.7%) | $73.23 M(-52.0%) | $68.40 M(-23.1%) |
| Sept 2017 | - | $152.71 M(+15.7%) | $88.94 M(-277.1%) |
| June 2017 | - | $132.03 M(-145.6%) | -$50.22 M(-68.8%) |
| Mar 2017 | - | -$289.56 M(-408.8%) | -$161.00 M(-220.8%) |
| Dec 2016 | $133.27 M(-29.5%) | $93.76 M(+591.8%) | $133.27 M(+44.6%) |
| Sept 2016 | - | $13.55 M(-36.2%) | $92.15 M(-28.2%) |
| June 2016 | - | $21.25 M(+352.0%) | $128.26 M(-10.4%) |
| Mar 2016 | - | $4.70 M(-91.1%) | $143.21 M(-24.2%) |
| Dec 2015 | $188.92 M(-65.6%) | $52.64 M(+6.0%) | $188.92 M(-22.7%) |
| Sept 2015 | - | $49.67 M(+37.2%) | $244.46 M(-55.7%) |
| June 2015 | - | $36.20 M(-28.2%) | $552.03 M(+0.5%) |
| Mar 2015 | - | $50.41 M(-53.4%) | $549.24 M(-0.0%) |
| Dec 2014 | $549.24 M(+121.1%) | $108.19 M(-69.7%) | $549.24 M(+4.6%) |
| Sept 2014 | - | $357.23 M(+969.4%) | $525.11 M(+190.3%) |
| June 2014 | - | $33.41 M(-33.7%) | $180.88 M(-40.7%) |
| Mar 2014 | - | $50.42 M(-40.0%) | $304.96 M(+22.8%) |
| Dec 2013 | $248.41 M(+44.3%) | $84.05 M(+546.3%) | $248.41 M(+46.8%) |
| Sept 2013 | - | $13.01 M(-91.7%) | $169.20 M(+3.0%) |
| June 2013 | - | $157.49 M(-2667.0%) | $164.34 M(+13.7%) |
| Mar 2013 | - | -$6.13 M(-226.8%) | $144.54 M(-16.1%) |
| Dec 2012 | $172.20 M(-238.6%) | $4.84 M(-40.7%) | $172.20 M(-1203.0%) |
| Sept 2012 | - | $8.15 M(-94.1%) | -$15.61 M(+322.7%) |
| June 2012 | - | $137.69 M(+539.7%) | -$3.69 M(-95.7%) |
| Mar 2012 | - | $21.52 M(-111.8%) | -$86.36 M(-30.5%) |
| Dec 2011 | -$124.24 M(-129.2%) | -$182.98 M(-1011.8%) | -$124.24 M(-282.2%) |
| Sept 2011 | - | $20.07 M(-63.5%) | $68.19 M(-84.7%) |
| June 2011 | - | $55.03 M(-436.4%) | $446.62 M(+11.4%) |
| Mar 2011 | - | -$16.36 M(-273.1%) | $401.06 M(-5.6%) |
| Dec 2010 | $425.06 M(-57.5%) | $9.45 M(-97.6%) | $425.06 M(-55.5%) |
| Sept 2010 | - | $398.50 M(+4106.6%) | $954.27 M(+39.0%) |
| June 2010 | - | $9.47 M(+24.0%) | $686.37 M(-0.2%) |
| Mar 2010 | - | $7.64 M(-98.6%) | $687.98 M(-31.1%) |
| Dec 2009 | $999.01 M(+60.9%) | $538.66 M(+312.5%) | $999.01 M(+110.7%) |
| Sept 2009 | - | $130.59 M(+1078.5%) | $474.06 M(-16.6%) |
| June 2009 | - | $11.08 M(-96.5%) | $568.43 M(+3.8%) |
| Mar 2009 | - | $318.67 M(+2223.5%) | $547.43 M(-11.8%) |
| Dec 2008 | $620.74 M | $13.71 M(-93.9%) | $620.74 M(+0.5%) |
| Sept 2008 | - | $224.96 M(-2368.2%) | $617.75 M(+71.4%) |
| June 2008 | - | -$9.92 M(-102.5%) | $360.39 M(-4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | $391.98 M(+3554.1%) | $378.44 M(-3813.9%) |
| Dec 2007 | -$10.19 M(-102.8%) | $10.73 M(-133.1%) | -$10.19 M(+54.0%) |
| Sept 2007 | - | -$32.40 M(-498.2%) | -$6.62 M(-101.9%) |
| June 2007 | - | $8.14 M(+143.3%) | $345.64 M(-0.4%) |
| Mar 2007 | - | $3.34 M(-76.6%) | $347.05 M(-5.1%) |
| Dec 2006 | $365.87 M(+85.3%) | $14.30 M(-95.5%) | $365.87 M(-0.4%) |
| Sept 2006 | - | $319.85 M(+3249.6%) | $367.20 M(+521.1%) |
| June 2006 | - | $9.55 M(-56.9%) | $59.12 M(-73.0%) |
| Mar 2006 | - | $22.16 M(+41.7%) | $219.04 M(+10.9%) |
| Dec 2005 | $197.46 M(-2389.1%) | $15.64 M(+32.9%) | $197.46 M(+6.6%) |
| Sept 2005 | - | $11.77 M(-93.1%) | $185.29 M(+7.5%) |
| June 2005 | - | $169.47 M(>+9900.0%) | $172.43 M(-2257.3%) |
| Mar 2005 | - | $572.00 K(-83.6%) | -$7.99 M(-7.3%) |
| Dec 2004 | -$8.63 M(-123.0%) | $3.48 M(-417.9%) | -$8.63 M(-288.5%) |
| Sept 2004 | - | -$1.09 M(-90.0%) | $4.58 M(-68.8%) |
| June 2004 | - | -$10.95 M(>+9900.0%) | $14.64 M(-44.5%) |
| Mar 2004 | - | -$61.00 K(-100.4%) | $26.40 M(-29.5%) |
| Dec 2003 | $37.47 M(+170.7%) | $16.68 M(+85.9%) | $37.47 M(+36.6%) |
| Sept 2003 | - | $8.97 M(+1016.2%) | $27.44 M(+42.2%) |
| June 2003 | - | $804.00 K(-92.7%) | $19.30 M(-17.1%) |
| Mar 2003 | - | $11.01 M(+65.6%) | $23.27 M(+68.1%) |
| Dec 2002 | $13.84 M(-376.3%) | $6.65 M(+698.1%) | $13.84 M(-246.9%) |
| Sept 2002 | - | $833.00 K(-82.6%) | -$9.42 M(+5.7%) |
| June 2002 | - | $4.78 M(+201.8%) | -$8.92 M(-19.0%) |
| Mar 2002 | - | $1.58 M(-109.5%) | -$11.02 M(+119.9%) |
| Dec 2001 | -$5.01 M(-100.8%) | -$16.62 M(-1342.0%) | -$5.01 M(-105.1%) |
| Sept 2001 | - | $1.34 M(-50.1%) | $97.50 M(-77.9%) |
| June 2001 | - | $2.68 M(-64.7%) | $441.65 M(-1.6%) |
| Mar 2001 | - | $7.59 M(-91.2%) | $448.86 M(-27.5%) |
| Dec 2000 | $619.33 M(>+9900.0%) | $85.89 M(-75.1%) | $619.33 M(+15.9%) |
| Sept 2000 | - | $345.49 M(+3395.4%) | $534.33 M(+181.5%) |
| June 2000 | - | $9.88 M(-94.4%) | $189.84 M(+5.3%) |
| Mar 2000 | - | $178.06 M(>+9900.0%) | $180.26 M(+6337.8%) |
| Dec 1999 | $2.80 M(-33.3%) | $900.00 K(-9.7%) | $2.80 M(+40.0%) |
| Sept 1999 | - | $997.00 K(+229.0%) | $2.00 M(-20.1%) |
| June 1999 | - | $303.00 K(-49.5%) | $2.50 M(-28.5%) |
| Mar 1999 | - | $600.00 K(+500.0%) | $3.50 M(-16.7%) |
| Dec 1998 | $4.20 M(-97.5%) | $100.00 K(-93.3%) | $4.20 M(-26.3%) |
| Sept 1998 | - | $1.50 M(+15.4%) | $5.70 M(+7.5%) |
| June 1998 | - | $1.30 M(0.0%) | $5.30 M(-66.9%) |
| Mar 1998 | - | $1.30 M(-18.8%) | $16.00 M(-90.3%) |
| Dec 1997 | $164.80 M(+89.2%) | $1.60 M(+45.5%) | $164.80 M(-0.6%) |
| Sept 1997 | - | $1.10 M(-90.8%) | $165.80 M(-31.7%) |
| June 1997 | - | $12.00 M(-92.0%) | $242.80 M(+2.5%) |
| Mar 1997 | - | $150.10 M(+5673.1%) | $236.80 M(+171.9%) |
| Dec 1996 | $87.10 M(+5023.5%) | $2.60 M(-96.7%) | $87.10 M(+2.2%) |
| Sept 1996 | - | $78.10 M(+1201.7%) | $85.20 M(+1100.0%) |
| June 1996 | - | $6.00 M(+1400.0%) | $7.10 M(+317.6%) |
| Mar 1996 | - | $400.00 K(-42.9%) | $1.70 M(0.0%) |
| Dec 1995 | $1.70 M(-97.6%) | $700.00 K(>+9900.0%) | $1.70 M(-89.3%) |
| Sept 1995 | - | $0.00(-100.0%) | $15.90 M(+1.9%) |
| June 1995 | - | $600.00 K(+50.0%) | $15.60 M(+5.4%) |
| Mar 1995 | - | $400.00 K(-97.3%) | $14.80 M(-79.4%) |
| Dec 1994 | $71.90 M(+4393.8%) | $14.90 M(-5066.7%) | $71.90 M(+27.0%) |
| Sept 1994 | - | -$300.00 K(+50.0%) | $56.60 M(+0.4%) |
| June 1994 | - | -$200.00 K(-100.3%) | $56.40 M(-5.2%) |
| Mar 1994 | - | $57.50 M(<-9900.0%) | $59.50 M(+3618.8%) |
| Dec 1993 | $1.60 M(-233.3%) | -$400.00 K(-20.0%) | $1.60 M(-5.9%) |
| Sept 1993 | - | -$500.00 K(-117.2%) | $1.70 M(-10.5%) |
| June 1993 | - | $2.90 M(-825.0%) | $1.90 M(-246.2%) |
| Mar 1993 | - | -$400.00 K(+33.3%) | -$1.30 M(+8.3%) |
| Dec 1992 | -$1.20 M(-102.4%) | -$300.00 K(0.0%) | -$1.20 M(+33.3%) |
| Sept 1992 | - | -$300.00 K(0.0%) | -$900.00 K(+50.0%) |
| June 1992 | - | -$300.00 K(0.0%) | -$600.00 K(+100.0%) |
| Mar 1992 | - | -$300.00 K | -$300.00 K |
| Dec 1991 | $50.90 M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual cash flow from financing activities?
- What is the all time high annual CFF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual CFF year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly CFF year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM cash flow from financing activities?
- What is the all time high TTM CFF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM CFF year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual cash flow from financing activities?
The current annual CFF of VRTX is -$562.20 M
What is the all time high annual CFF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual cash flow from financing activities is $999.01 M
What is Vertex Pharmaceuticals Incorporated annual CFF year-on-year change?
Over the past year, VRTX annual cash flow from financing activities has changed by -$494.50 M (-730.43%)
What is Vertex Pharmaceuticals Incorporated quarterly cash flow from financing activities?
The current quarterly CFF of VRTX is -$387.50 M
What is the all time high quarterly CFF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly cash flow from financing activities is $538.66 M
What is Vertex Pharmaceuticals Incorporated quarterly CFF year-on-year change?
Over the past year, VRTX quarterly cash flow from financing activities has changed by -$222.50 M (-134.85%)
What is Vertex Pharmaceuticals Incorporated TTM cash flow from financing activities?
The current TTM CFF of VRTX is -$1.22 B
What is the all time high TTM CFF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM cash flow from financing activities is $999.01 M
What is Vertex Pharmaceuticals Incorporated TTM CFF year-on-year change?
Over the past year, VRTX TTM cash flow from financing activities has changed by -$821.20 M (-204.18%)